Corient Private Wealth
CCCC icon

Corient Private Wealth’s C4 Therapeutics CCCC Stock Holding History

Corient Private Wealth’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.7K Sell
10,007
-11,380
-53% -$38.9K ﹤0.01% 2994
2026
Q1 		$56.2K Hold
21,387
– – ﹤0.01% 2748
2025
Q4 		$40.9K Sell
21,387
-1,315
-6% -$3.12K ﹤0.01% 2609
2025
Q3 		$50.4K Buy
22,702
+10,007
+79% +$24K ﹤0.01% 2500
2025
Q2 		$18.2K Sell
12,695
-50
-0.4% -$73 ﹤0.01% 2411
2025
Q1 		$20.4K Buy
12,745
+50
+0.4% +$149 ﹤0.01% 2255
2024
Q4 		$45.7K Hold
12,695
– – ﹤0.01% 2283
2024
Q3 		$72.4K Hold
12,695
– – ﹤0.01% 2362
2024
Q2 		$58.7K Hold
12,695
– – ﹤0.01% 2247
2024
Q1 		$104K Hold
12,695
– – ﹤0.01% 2183
2023
Q4 		$71.7K Hold
12,695
– – ﹤0.01% 2177
2023
Q3 		$23.6K Buy
+12,695
New +$38.7K ﹤0.01% 2106
2023
Q2 		– Sell
-12,695
Closed -$39.9K – 2087
2023
Q1 		$39.9K Buy
12,695
+1,315
+12% +$7.74K ﹤0.01% 1953
2022
Q4 		$67.1K Buy
+11,380
New +$94.4K ﹤0.01% 1605

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Corient Private Wealth's CCCC Position: Q2 2026 in Review

Corient Private Wealth reduced its C4 Therapeutics (CCCC) stake by 53% in Q2 2026, selling an estimated $38.9K and leaving 10,007 shares worth $46.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Corient Private Wealth first reported a position in CCCC in Q4 2022 and has held it in 14 quarters since. The position peaked at $104K in Q1 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Corient Private Wealth held 10,007 shares of C4 Therapeutics worth $46.7K as of Q2 2026.
  • Corient Private Wealth sold 11,380 C4 Therapeutics shares in Q2 2026, an estimated $38.9K.
  • C4 Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2994 holding.
  • Corient Private Wealth first reported a position in C4 Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's C4 Therapeutics position peaked at $104K in Q1 2024.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.